Sign up to save your podcasts
Or
Share E49: IL17i vs. TNFi for Psoriatic Arthritis (SPIRIT-H2H)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
E49: IL17i vs. TNFi for Psoriatic Arthritis (SPIRIT-H2H)
Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).
View all episodes
By Michael Putman
4.9
111111 ratings
Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).
More shows like The Evidence Based Rheumatology Podcast
View all
NEJM This Week
315 Listeners
JAMA Clinical Reviews
497 Listeners
Rheumnow Podcast
124 Listeners
The Curbsiders Internal Medicine Podcast
3,323 Listeners
Core IM | Internal Medicine Podcast
1,103 Listeners
Healio Rheuminations
119 Listeners
Annals On Call Podcast
195 Listeners
The Clinical Problem Solvers
516 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
Freely Filtered, a NephJC Podcast
168 Listeners
ACR on Air
70 Listeners
Around the Rheum
4 Listeners
Rheumatology For The Royal College
174 Listeners
Talking Rheumatology Spotlight
6 Listeners
ACR Journals On Air
19 Listeners